<div id="readability-page-1"><p><span>Dyne Therapeutics (NASDAQ:DYN - Get Free Report)</span> was upgraded by investment analysts at Wall Street Zen from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a report released on Saturday.</p><div><p><span></span><span>Get <strong>Dyne Therapeutics</strong> alerts:</span></p></div><p>A number of other research analysts also recently commented on the stock. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Chardan Capital  reissued a &#34;buy&#34; rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Jefferies Financial Group  reissued a &#34;buy&#34; rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein lifted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a &#34;market perform&#34; rating in a research report on Wednesday. Finally, JPMorgan Chase &amp; Co. decreased their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued  a Buy rating, two have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $35.00.</p><p><b>Get Our Latest Research Report on DYN</b></p><h2>Dyne Therapeutics Stock Down 5.4%</h2><p>Dyne Therapeutics stock opened at $17.29 on Friday. The company has a market cap of $2.86 billion, a P/E ratio of -5.37 and a beta of 1.08. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a fifty day simple moving average of $18.34 and a 200 day simple moving average of $18.63. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. </p><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company posted ($1.05) earnings per share.  Research analysts anticipate that  Dyne Therapeutics will post -2.99 earnings per share for the current fiscal year. </p><h2>Insider Activity at Dyne Therapeutics</h2><p>In related news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the completion of the sale, the director owned 11,663 shares of the company's stock, valued at approximately $229,527.84. The trade was a 96.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,559,462 shares of company stock valued at $29,814,746. Company insiders own  14.14% of the company's stock. </p><h2>Hedge Funds Weigh In On Dyne Therapeutics</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in  Dyne Therapeutics during the 1st quarter worth approximately $246,000.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in  Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock valued at $597,000 after buying an additional 2,886 shares in the last quarter.  Goldman Sachs Group Inc. increased its position in  Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after buying an additional 366,183 shares during the period.  Caxton Associates LLP bought a new position in  Dyne Therapeutics during the 1st quarter worth $157,000.  Finally, Creative Planning lifted its holdings in shares of  Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company's stock worth $138,000 after buying an additional 2,797 shares in the last quarter. Institutional investors and hedge funds own  96.68% of the company's stock. </p><h2>Key Headlines Impacting Dyne Therapeutics</h2><p>Here are the key news stories impacting Dyne Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>HC Wainwright reiterated a <strong>Buy</strong> rating and <strong>$50 price target</strong> on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.</li>   <li><span>Positive Sentiment: </span>Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.</li>   <li><span>Neutral Sentiment: </span>Dyne Therapeutics’ average brokerage rating remains <strong>Moderate Buy</strong>, indicating Wall Street sentiment is still constructive overall. <i></i><span>Dyne Therapeutics, Inc. <span>NASDAQ: DYN<span></span></span> Given Average Rating of &#34;Moderate Buy&#34; by Brokerages</span></li>   <li><span>Neutral Sentiment: </span>The company recently reported a quarterly loss that was <strong>slightly better than expected</strong>, which is supportive but not a major catalyst on its own.</li>   <li><span>Negative Sentiment: </span>CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.</li> </ul><h2>Dyne Therapeutics Company Profile</h2> (Get Free Report)<p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.  </p><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Dyne Therapeutics</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li><li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

LABU

<p>Wall Street Zen upgraded Dyne Therapeutics (NASDAQ:DYN) from a 'strong sell' to a 'sell' rating. Other analysts have varied opinions, with Weiss Ratings maintaining a 'sell' and Chardan Capital issuing a 'buy' with a $38 price target. Dyne's stock opened at $17.29, with a market cap of $2.86 billion. The company reported earnings of ($0.73) per share, beating estimates. Insider trading saw significant share sales, and institutional investors hold 96.68% of the stock.</p>

Dyne Therapeutics (NASDAQ:DYN) Upgraded at Wall Street Zen